A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

1. Balzarotti, M.
2. Magagnoli, M.
3. Canales, M.Á.
4. Corradini, P.
5. Grande, C.
6. Sancho, J.-M.
7. Zaja, F.
8. Quinson, A.-M.
9. Belsack, V.
10. Maier, D.
11. Carlo-Stella, C.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1007/S10637-020-01054-6 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus